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A b s t r a c t: Wilson disease (WD) is an autosomal recessive disorder, in which 
copper is deposited in the liver, brain, cornea and kidneys. The clinical presentation is 
variable, with fully expressed disease manifesting cirrhosis, neurologic damage and 
Kayser-Fleischer (K-F) ring on the cornea.  
A 24-year-old patient developed right upper quadrant pain with a palpable 
mass and a swelling of the right talocrural articulation. X-rays were uneventful, but the 
routine examination of hepatic enzymes discovered a 6–8 fold increase in SGPT, SGOT 
and AST. Antibodies for hepatitis B, C were normal, as well as the ANA, ANCA, 
antimytochondrial and anti-smooth muscle antibodies. Ultrasound of the abdomen reve-
aled extremely dilated hepatic, cystic ducts as well as gallbladder. A large, oedematous 
gallbladder with yellow green bile was removed, the liver was found to be cirrhotic, but 
as the operative bleeding was abundant a biopsy was not done. Serum ceruloplasmin 
was low [0.160 g/l (normal 0.204–0.407)], serum copper 12.7 μmol/l (11.0–24.4), tran-
saminasis: always very high, in the last months normal/slightly elevated. Urine copper: 
1.0 μmol/24h (> 9.44). As first seen the proband had tremor, dysarthria, dystonia and K-
F ring on the cornea. After 10 months of treatment with penicillamine his transaminases 
normalized, the tremor, dysarthria, dystonia initially got worse and then ameliorated. 
The coagulation times are ameliorated, but not yet normalized. Mutational analysis has 
shown that the proband is homozygote for c.3207 C- > A, p.H1069Q while his parents 
are heterozygotes. His sister is a healthy non-carrier. In brief, we describe an unusual 
presentation of WD, with gallbladder hydrops and talocrural arthritis in a patient with 
complete clinical manifestations of the disease.  
 
Key words: Wilson disease, Kayser-Fleischer rings, gallbladder hydrops. arthritis, 
p.H1069Q mutation.  
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Introduction 
 
Wilson disease (WD) is an autosomal recessive disorder of copper me-
tabolism. WD causes toxic accumulation of copper in the liver, brain, cornea 
and kidney. Progressive liver cirrhosis, neurologic impairment, and Kayser-
Fleischer (K-F) rings and/or renal malfunction are the classical clinical presen-
tations of WD [1, 2].  
Prophylactic therapy in affected but presymptomatic patients can prevent 
the onset of symptoms [3]. Therefore, early diagnosis is essential. The standard 
clinical and biochemical tests and the liver biopsy for hepatic copper analysis may 
give false-positive results. In addition, those tests cannot be applied in pre-
symptomatic diagnosis. Molecular diagnosis overcomes these limitations.  
We here present a late diagnosis of WD in a young man with an unusual 
presentation of WD: gallbladder hydrops and talocrural arthritis, having all 
three major clinical presentations: cirrhosis, neurologic signs and K-F rings. In 
addition, this is the first Macedonian patient with a mutational diagnosis. Na-
mely, the most common mutation of the in the ATP7B gene in the central Euro-





This 24-year-old patient developed a swelling of the right talocrural 
articulation and right upper quadrant pain with a palpable mass. Fever, vomiting 
and jaundice were not present. X-rays were uneventful, but the routine examina-
tion of hepatic enzymes discovered a 6–8 fold increase in SGPT, SGOT and 
AST. Antibodies for hepatitis B, C (HBsAg, HbeAg and antibodies to HCV an-
tigens) were normal, as well as the anti-neutrofil cytoplasmic antibodies (ANCA), 
antimytochondrial, antiactin (anti smooth muscle), antinuclear (ANA), anti-liver-
kidney antibodies. Ultrasound of the abdomen revealed hyperechogenic liver 
parenchyma and an extremely distended, echo-free gallbladder, with dilatation 
of the biliary three (hepatic and cystic ducts). The gallbladder was surgically 
extracted (a large, oedematous gallbladder with yellow green bile), the liver was 
found cirrhotic, but as the operative bleeding was abundant a biopsy of the liver 
was not done. Serum ceruloplasmin was low [0.160 g/l (normal 0.204–0.407)], 
serrum copper 12.7 μmol/l (11.0–24.4), transaminasis: always very high, in the 
last months normal/slightly elevated. Urine copper: 1.0 μmol/24h (> 9.44). Hae-
moglobin, erythrocytes, serum ferrum, creatinin and urea remained normal thro-
ughout the course of the disease. The proband had intention tremor, dysarthria 
and dystonia. Kayser-Fleischer ring on the cornea was also noted. After 10 
months of treatment with penicillamine his transaminases normalized, the tre-
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mor, dysarthria and dystonia initially worsened and then ameliorated. The coa-
gulation times are ameliorated (near normal), but not fully normalized. In addi-
tion he receives alpha tocopherol, vitamin B, K, C. Mutational analysis has 
shown that the proband is homozygote for c.3207 C- > A, p.H1069Q while his 





The estimated WD frequency in the U.S. Caucasian population was 
found to be about 1 in 55, 000 births [4]. The prevalence in the European popu-
lations is estimated to be around 1 in 30,000, while a higher prevalence of WD 
(1 in 2,600) was found in the northeastern region of the island of Gran Canaria 
(Spain) [5]. The prevalence of WD was estimated to be 1 in 5,400 in Hong 
Kong Han Chinese [6]. In general, the worldwide prevalence of Wilson disease 
is estimated to be in the order of 30 per 1 million. This is the first description of 
WD with mutational analysis in Macedonia.  
WD results in accumulation of copper in the liver and brain when a 
membrane-bound copper transporter, ATP7B, is defective. ATP7B is expressed 
in hepatic, brain and kidney cells, and a defect can lead to liver, neurological 
and renal damage in WND patients.  
To date, there are approximately 380 probable disease-causing variants 
in the ATP7B gene [6–18]. The most common mutation in patients from Europe 
is H1069Q [19]. A 15-bp deletion in the 5-prime region is frequent in Sardinia. 
Some other mutations are found to be more frequent in certain populations: 
M645R is common in Spain, R778L in patients from eastern Asia. The common 
his1069-to-gln mutation accounted for 42% of all WD patients in the German 
series [20]. In the U.S. Caucasian population approximately one-third of WD 
mutations are his1069-to-gln [4]. The Macedonian patient of Serbian and Mace-
donian extraction also had his1069-to-gln mutation.  
Presentation is variable with a broad range of age of onset and symp-
toms, and not all biochemical signs used in diagnosis are found in every patient. 
It is generally agreed that WD should be considered in any patient at any age 
presenting with unusual liver or neurological abnormalities. As KFR is present 
in 100% of patients with CNS manifestations of WD, slit-lamp assessment is 
mandatory. WD has been described in children, adolescents and in the older age 
group [21, 22].  
It was suggested that there are at least 3 forms of WD [23]. The rare 
"atypical form", with heterozygotes showing about 50% of the normal level of 
ceruloplasmin, and a probable German-Mennonite derivation. The second "typi-
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cal form" is the Slavic type with a late age of onset and predominantly neuro-
logic manifestations, while the third "typical" form is the juvenile type, which 
occurs mostly in Western Europeans, has its onset before the age of 16 years 
and is often hepatic. Others have also observed the existence of neurological, 
hepatic, and the hepatoneurologic type of WD [24]. Fulminant hepatic failure 
has also been reported [25, 26]. Other ethnic differences have also been obser-
ved: Jewish patients with later onset and milder disease [27], while Arab pati-
ents had an earlier onset and more severe course [28].  
Myocardial involvements in WD include increased thickness of the in-
terventricular septum and left ventricular posterior wall, as well as cardiac arryth-
mias [29, 30]. Polyneuropathy before developing more typical symptoms of 
WD was also reported [31]. Occasionally, hypercalciuria associated with WD 
was also found [32–34].  
Osteoarthritis and chondrocalcinosis has been infrequently reported in 
WD, and was speculated to result from accumulation similar to the arthropathy 
of hemochromatosis [36]. Osteoarthritis as initial WD manifestation has not, to 
the best of our knowledge, so far been reported.  
MRI scans show abnormalities of the basal ganglia, generalized cere-
bral atrophy, and white matter abnormalities in some WD patients, particularly 
at the dentatorubrothalamic, pontocerebellar, and corticospinal tracts [37]. Leu-
koencephalopathy was also reported [38].  
Since our patient was found to have only low ceruloplasmin levels, 
while copper in serum and urine was normal, genetic analysis was particulary 
important. The mutational analysis confirmed the diagnosis, as well as the 
observation that patients homozygous for the his1069-to-gln mutation have an 
almost complete range of clinical presentations [20].  
Wilson disease can be effectively treated [39]. Penicillamine in presymp-
tomatic and symptomatic patients is effective. However, penicillamine may lead 
to adverse effects involving the immune system or connective tissue. Also, it 
can cause the onset of neurological disease or worsening of neurological mani-
festations in symptomatic patients (as happened with our patient) when used in 
the initial therapy. Because of its adverse effects in some patients it is necessary 
to replace the treatment with triethylene tetramine (TETA) [40].  
Zinc has been developed as an effective and nontoxic therapy in WD 
that blocks the absorption of copper and increases copper excretion in the stool 
[41]. Tetrathiomolybdate has shown excellent efficacy in patients with Wilson 
disease who presented with neurologic manifestations [41–43]. The adverse ef-
fects include bone marrow suppression or aminotransferase elevations.  
WD has been successfully treated with an orthotopic liver transplant 
[44, 45]. However, postoperative central pontine and extrapontine myelinolysis 
has been reported [46].  
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The outcome of the treatment is difficult to foresee. Although treatable, 
WD remains a challenge for treatment, with a still high mortality. In a series of 
142 patients, there have been 30 deaths: the cumulative probability of survival 
over a 15-year period was found to be 76.7 +/- 4.9% [47]. 
Our patient is so far being successfully treated with penicillamine. The 
neurologic manifestations are ameliorated, the hepatic enzymes normalized and 
the coagulation analysis ameliorated (near normalized). In conclusion, we pre-
sent a young man of 24 years with initial WD manifestations of gallbladder 
hydrops and arthritis. To the best of our knowledge those initial WD manifesta-
tions have not so far been described.  
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KAKO NEVOOBI^AENI MANIFESTACII  
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A p s t r a k t: Bolesta na Vilson e avtosomno recesivno naru{uvawe 
kaj koe bakarot se deponira vo crniot drob, mozokot, korenite, bubrezite. 
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Klini~kite manifestacii se varijabilni i vklu~uvaat ciroza, nevro-
lo{ki o{tetuvawa i karakteristi~en Kajzer-Flaj{erov prsten na ro~-
nicite. Prika`aniot 24-godi{en pacient inicijalno se zdobil so bolka vo 
gorniot stoma~en kvadrant i palpabilna masa pod desniot rebren lak, kako 
i bolki vo talokruralniot zglob. Hepatalnite enzimi bea poka~eni 6‡8 
pati. Antitelata za hepatit B i C, ANA, ANKA, antimitohondrijalnite 
antitela i anti glatko muskulnite antitela bea so normalni vrednosti. 
Ehosonografski bea najdeni ekstremno dilatirani hepati~niot, cisti~-
niot duktus, kako i `ol~noto kese. So hirur{ka intervencija be{e otstra-
neta golema, ote~ena `ol~na }esa so `olto-zelena `ol~ka. Crniot drob 
be{e ciroti~en {to dovede do zna~itelno operativno krvavewe koe one-
vozmo`i intraoperativna crnodrobna biopsija. Serumskiot ceruloplaz-
min be{e nizok [0,160 g/l (normal 0,204–0,407)], serumskiot bakar normalen 
12,7 μmol/l (11,0–24,4). Bakarot vo urinata nizok: 1,0 μmol/24 h (> 9,44). Pri 
prviot pregled pacientot ima{e premor, dizartrija, distonija i K-F prs-
ten na ro`nicata. Po 10-mese~no lekuvawe so penicilamin negovite tran-
saminazi se normaliziraa, a koagulacionite vrednosti se podobrija. Muta-
cionata analiza kaj pacientot poka`a deka e homozigot za mutacijata c.3207 
C- > A, p.H1069Q, dodeka negovite roditeli se poka`aa heterozigoti. Nego-
vata sestra e zdrava i ne e nositel na mutacijatata. Nakuso opi{uvame ne-
voobi~aena prezentacija na bolesta na Vilson so hidrops na `ol~noto 
}ese, talokruralen artrit, nekompletni biohemiski manifestacii, no 
kompletna karakteristi~na slika na bolesta.  
 
Klu~ni zborovi: Vilsonova bolest, Kajzer-Flaj{erov prsten, hidrops na 
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